

Swen Hesse

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3379771/publications.pdf>

Version: 2024-02-01

79
papers

2,850
citations

147801

31
h-index

197818

49
g-index

88
all docs

88
docs citations

88
times ranked

3561
citing authors

#	ARTICLE	IF	CITATIONS
1	PET Imaging of Cholinergic Neurotransmission in Neurodegenerative Disorders. <i>Journal of Nuclear Medicine</i> , 2022, 63, 33S-44S.	5.0	21
2	Effects of Hyperthyroidism on Adipose Tissue Activity and Distribution in Adults. <i>Thyroid</i> , 2021, 31, 519-527.	4.5	7
3	<scp>JuSpace</scp>: A tool for spatial correlation analyses of magnetic resonance imaging data with nuclear imaging derived neurotransmitter maps. <i>Human Brain Mapping</i> , 2021, 42, 555-566.	3.6	95
4	(+)-[18F]Flubatine as a novel $\alpha 4\beta 2$ nicotinic acetylcholine receptor PET ligand—results of the first-in-human brain imaging application in patients with $\beta 2$ -amyloid PET-confirmed Alzheimer's disease and healthy controls. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 731-746.	6.4	10
5	Striatal dopamine transporter availability and individual clinical course within the 1-year follow-up of deep brain stimulation of the subthalamic nucleus in patients with Parkinson's disease. <i>Journal of Neurosurgery</i> , 2021, , 1-7.	1.6	2
6	Cognitive fatigue in multiple sclerosis is associated with alterations in the functional connectivity of monoamine circuits. <i>Brain Communications</i> , 2021, 3, fcab023.	3.3	20
7	Central Noradrenergic Neurotransmission and Weight Loss 6 Months After Gastric Bypass Surgery in Patients with Severe Obesity. <i>Obesity Surgery</i> , 2021, 31, 4868-4876.	2.1	4
8	Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [18F] fluspidine and [18F] fallypride PET study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1103-1115.	6.4	28
9	Changes of central noradrenaline transporter availability in immunotherapy-naïve multiple sclerosis patients. <i>Scientific Reports</i> , 2020, 10, 14651.	3.3	6
10	Higher HbA1c levels associate with lower hippocampal serotonin transporter availability in non-diabetic adults with obesity. <i>Scientific Reports</i> , 2020, 10, 21383.	3.3	0
11	JuSpace: A Tool for Spatial Correlation Analyses of Functional and Structural Magnetic Resonance Imaging Data With Positron Emission Tomography Derived Receptor Maps. <i>Biological Psychiatry</i> , 2020, 87, S190.	1.3	4
12	Unravelling the effects of methylphenidate on the dopaminergic and noradrenergic functional circuits. <i>Neuropsychopharmacology</i> , 2020, 45, 1482-1489.	5.4	17
13	Current radiotracers to image neurodegenerative diseases. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2019, 4, 17.	3.9	28
14	Adult attention-deficit/hyperactivity disorder is associated with reduced norepinephrine transporter availability in right attention networks: a (S,S)-O-[11C]methylreboxetine positron emission tomography study. <i>Translational Psychiatry</i> , 2019, 9, 301.	4.8	29
15	In vitro and in vivo Human Metabolism of (S)-[18F]Fluspidine—A Radioligand for Imaging $\beta 1$ Receptors With Positron Emission Tomography (PET). <i>Frontiers in Pharmacology</i> , 2019, 10, 534.	3.5	9
16	Early after Administration [11C]PiB PET Images Correlate with Cognitive Dysfunction Measured by the CERAD Test Battery. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 65-76.	2.6	4
17	Central noradrenaline transporter availability is linked with HPA axis responsiveness and copeptin in human obesity and non-obese controls. <i>Stress</i> , 2019, 22, 93-102.	1.8	9
18	Noradrenaline transporter availability on [11C]MRB PET predicts weight loss success in highly obese adults. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1618-1625.	6.4	7

#	ARTICLE	IF	CITATIONS
19	Cognitive correlates of $\alpha 2$ nicotinic acetylcholine receptors in mild Alzheimer's dementia. <i>Brain</i> , 2018, 141, 1840-1854.	7.6	60
20	Dual Time-Point [18F]Florbetaben PET Delivers Dual Biomarker Information in Mild Cognitive Impairment and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1105-1116.	2.6	20
21	Dissociation Between Brown Adipose Tissue β -FDG Uptake and Thermogenesis in Uncoupling Protein 1-Deficient Mice. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1100-1103.	5.0	73
22	Central noradrenaline transporter availability in highly obese, non-depressed individuals. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1056-1064.	6.4	50
23	Post-dexamethasone serum copeptin corresponds to HPA axis responsiveness in human obesity. <i>Psychoneuroendocrinology</i> , 2017, 78, 39-47.	2.7	9
24	The impact of reconstruction and scanner characterisation on the diagnostic capability of a normal database for [123I]FP-CIT SPECT imaging. <i>EJNMMI Research</i> , 2017, 7, 10.	2.5	16
25	Test-retest measurements of dopamine D1-type receptors using simultaneous PET/MRI imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1025-1032.	6.4	50
26	The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 353-357.	6.4	44
27	Gastric Bypass Surgery Recruits a Gut PPAR-Striatal D1R Pathway to Reduce Fat Appetite in Obese Rats. <i>Cell Metabolism</i> , 2017, 25, 335-344.	16.2	108
28	The association between in vivo central noradrenaline transporter availability and trait impulsivity. <i>Psychiatry Research - Neuroimaging</i> , 2017, 267, 9-14.	1.8	11
29	[123I]FP-CIT ENC-DAT normal database: the impact of the reconstruction and quantification methods. <i>EJNMMI Physics</i> , 2017, 4, 8.	2.7	46
30	News and views on in-vivo imaging of neurotransmission using PET and MRI. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 61, 414-428.	0.7	20
31	Evaluation of the Enantiomer Specific Biokinetics and Radiation Doses of [18F]Fluspidine: A New Tracer in Clinical Translation for Imaging of β 1 Receptors. <i>Molecules</i> , 2016, 21, 1164.	3.8	34
32	A novel thermoregulatory role for PDE 10A in mouse and human adipocytes. <i>EMBO Molecular Medicine</i> , 2016, 8, 796-812.	6.9	34
33	Central serotonin transporter availability in highly obese individuals compared with non-obese controls: A [11C] DASB positron emission tomography study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1096-1104.	6.4	22
34	Early [18F]florbetaben and [11C]PIB PET images are a surrogate biomarker of neuronal injury in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1700-1709.	6.4	69
35	Role of 18F-FDG-PET imaging in the diagnosis of autoimmune encephalitis. <i>Lancet Neurology</i> , The, 2016, 15, 1009-1010.	10.2	56
36	Effortful control as a dimension of temperament is negatively associated with prefrontal serotonin transporter availability in obese and non-obese individuals. <i>European Journal of Neuroscience</i> , 2016, 44, 2460-2466.	2.6	6

#	ARTICLE	IF	CITATIONS
37	Feasibility and acceptance of simultaneous amyloid PET/MRI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2236-2243.	6.4	25
38	The effect of serum BDNF levels on central serotonin transporter availability in obese versus non-obese adults: A [¹¹ C]DASB positron emission tomography study. <i>Neuropharmacology</i> , 2016, 110, 530-536.	4.1	13
39	In-vivo serotonin transporter availability and somatization in healthy subjects. <i>Personality and Individual Differences</i> , 2016, 94, 354-359.	2.9	3
40	Implementation of the European multicentre database of healthy controls for [¹²³ I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1315-1322.	6.4	29
41	Robust, fully automatic delineation of the head contour by stereotactical normalization for attenuation correction according to Chang in dopamine transporter scintigraphy. <i>European Radiology</i> , 2015, 25, 2709-2717.	4.5	4
42	The Effects of Thyroid Hormones on Gene Expression of Acyl-Coenzyme A Thioesterases in Adipose Tissue and Liver of Mice. <i>European Thyroid Journal</i> , 2015, 4, 59-66.	2.4	12
43	Distinctive striatal dopamine signaling after dieting and gastric bypass. <i>Trends in Endocrinology and Metabolism</i> , 2015, 26, 223-230.	7.1	12
44	First-in-human PET quantification study of cerebral $\alpha_4\beta_2$ nicotinic acetylcholine receptors using the novel specific radioligand (¹⁸ F)Flubatine. <i>NeuroImage</i> , 2015, 118, 199-208.	4.2	49
45	CT-Based Attenuation Correction in I-123-Ioflupane SPECT. <i>PLoS ONE</i> , 2014, 9, e108328.	2.5	24
46	Distinctive In Vivo Kinetics of the New α_1 Receptor Ligands (+)- and (-)- ¹⁸ F-Fluspidine in Porcine Brain. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1730-1736.	5.0	26
47	Altered serotonin transporter availability in patients with multiple sclerosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 827-835.	6.4	56
48	Extrastriatal binding of [¹²³ I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1938-1946.	6.4	60
49	Evaluation of metabolism, plasma protein binding and other biological parameters after administration of (¹⁸ F)Flubatine in humans. <i>Nuclear Medicine and Biology</i> , 2014, 41, 489-494.	0.6	18
50	Association of central serotonin transporter availability and body mass index in healthy Europeans. <i>European Neuropsychopharmacology</i> , 2014, 24, 1240-1247.	0.7	34
51	Comments on Eusebio et al.: Voxel-based analysis of whole-brain effects of age and gender on dopamine transporter SPECT imaging in healthy subjects. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 143-144.	6.4	2
52	No association between striatal dopamine transporter binding and body mass index: A multi-center European study in healthy volunteers. <i>NeuroImage</i> , 2013, 64, 61-67.	4.2	47
53	[¹²³ I]FP-CIT SPECT in atypical degenerative parkinsonism. <i>Imaging in Medicine</i> , 2012, 4, 411-421.	0.0	3
54	Imaging of the brain serotonin transporters (SERT) with ¹⁸ F-labelled fluoromethyl-McN5652 and PET in humans. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1001-1011.	6.4	30

#	ARTICLE	IF	CITATIONS
55	Impact of EEG-vigilance on brain glucose uptake measured with [18F]FDG and PET in patients with depressive episode or mild cognitive impairment. <i>NeuroImage</i> , 2011, 56, 93-101.	4.2	49
56	Preserved serotonin transporter binding in de novo Parkinson's disease: negative correlation with the dopamine transporter. <i>Journal of Neurology</i> , 2011, 258, 19-26.	3.6	65
57	Decreased cerebral ^{123}I -nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 515-525.	6.4	109
58	The serotonin transporter availability in untreated early-onset and late-onset patients with obsessive-compulsive disorder. <i>International Journal of Neuropsychopharmacology</i> , 2011, 14, 606-617.	2.1	53
59	Dopamine transporter imaging in adult patients with attention-deficit/hyperactivity disorder. <i>Psychiatry Research - Neuroimaging</i> , 2009, 171, 120-128.	1.8	61
60	Monoamine transporter availability in Parkinson's disease patients with or without depression. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 428-435.	6.4	72
61	Effects of subthalamic nucleus stimulation on striatal dopaminergic transmission in patients with Parkinson's disease within one-year follow-up. <i>Journal of Neurology</i> , 2008, 255, 1059-1066.	3.6	27
62	Kinetic analyses of [123I]IBZM SPECT for quantification of striatal dopamine D2 receptor binding: A critical evaluation of the single-scan approach. <i>NeuroImage</i> , 2008, 42, 548-558.	4.2	17
63	Serotonin Transporter Imaging with [¹²³ I]-CIT SPECT before and after One Year of Citalopram Treatment of Obsessive-Compulsive Disorder. <i>Neuropsychobiology</i> , 2006, 53, 40-45.	1.9	28
64	Neuroimaging of the Serotonin Transporter: Possibilities and Pitfalls. <i>Current Psychiatry Reviews</i> , 2006, 2, 111-149.	0.9	25
65	Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder. <i>Psychiatry Research - Neuroimaging</i> , 2005, 140, 63-72.	1.8	132
66	Nicotinic acetylcholine receptors in patients with Parkinson's disease and Alzheimer's disease: Specific binding of 2-[18F]F-A-85380 in the cerebral white matter as demonstrated by PET and comparison with diffusion tensor MRI (DTI). <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S584-S584.	4.3	0
67	Reduced serotonin transporter availability in obsessive-compulsive disorder (OCD). <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004, 254, 252-5.	3.2	66
68	Advances in in vivo imaging of serotonergic neurons in neuropsychiatric disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2004, 28, 547-563.	6.1	59
69	123I-beta-CIT SPECT for imaging serotonin transporters in Parkinson's disease. <i>Journal of Nuclear Medicine</i> , 2004, 45, 923-4.	5.0	1
70	Is correction for age necessary in neuroimaging studies of the central serotonin transporter?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 427-430.	6.4	49
71	Concordant pre- and postsynaptic deficits of dopaminergic neurotransmission in neurologic Wilson disease. <i>American Journal of Neuroradiology</i> , 2003, 24, 234-8.	2.4	51
72	Correlation between automated writing movements and striatal dopaminergic innervation in patients with Wilson's disease. <i>Journal of Neurology</i> , 2002, 249, 1082-1087.	3.6	19

#	ARTICLE	IF	CITATIONS
73	Prospective Value of Perfusion and X-Ray Attenuation Imaging With Single-Photon Emission and Transmission Computed Tomography in Acute Cerebral Ischemia. <i>Stroke</i> , 2001, 32, 1588-1597.	2.0	21
74	Positron emission tomography with [18F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. <i>Hepatology</i> , 2001, 33, 1029-1035.	7.3	239
75	Potential of Rheopheresis for the Treatment of Acute Ischemic Stroke When Initiated Between 6 and 12 Hours. <i>Therapeutic Apheresis and Dialysis</i> , 2000, 4, 358-362.	0.6	2
76	Reperfusion and Metabolic Recovery of Brain Tissue and Clinical Outcome After Ischemic Stroke and Thrombolytic Therapy. <i>Stroke</i> , 2000, 31, 1545-1551.	2.0	39
77	Extracorporeal Rheopheresis in the Treatment of Acute Ischemic Stroke. <i>Stroke</i> , 1999, 30, 787-792.	2.0	15
78	Differentiation between Transient Ischemic Attack and Ischemic Stroke within the First Six Hours after Onset of Symptoms by Using ^{99m} Tc-ECD-SPECT. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1998, 18, 921-929.	4.3	50
79	^{99m} Tc-Technetium-Ethyl-Cysteinate-Dimer Single-Photon Emission CT Can Predict Fatal Ischemic Brain Edema. <i>Stroke</i> , 1998, 29, 2556-2562.	2.0	110